The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

J&J loses early bid to escape Pfizer's Remicade biosimilars lawsuit.....           Alnylam vows value-based pricing, financial help with $450K Onpattro launch.....           CVS' move to lean on ICER data could mean dramatic shift in drug pricing leverage.....           Roche's Xolair, challenged in asthma, wins 'breakthrough' in food allergies.....           Bavarian Nordic secures ?30M loan as it expands plant to bring Imvamune manufacturing entirely in-house.....           NICE cost watchdogs spurn Biogen's pricey Spinraza, but leave door open for a deal.....           Salix, US WorldMeds eye 2019 push into the mainstream for opioid withdrawal drug Lucemyra.....           Outcome's image rehab rolls on with Nielsen deal for first-ever POC audience tallies.....           Amid pricing spat with U.K. government, Vertex won't ask NICE to approve its new CF drug.....           FiercePharmaAsia?Lenvima growth; China?s drug invite; Samsung?s biologics commitment.....           Amid pricing spat with U.K. government, Vertex declines to submit data on new CF drug to NICE.....           Pfizer's Besponsa, Lilly's Taltz rack up reimbursement wins at NICE.....           Express Scripts? new formulary ejects some drugs once thought 'untouchable': analysts.....           States say Alvogen lawsuit is part of a 'guerilla' war against the death penalty.....           FDA found big problems a year ago at Chinese plant now recalling tainted valsartan.....           Pharma watchers on Twitter chat up Johnson & Johnson Xarelto TV ad that seems 'misleading'.....           Bausch Health aims top-seller Xifaxan at new diseases to pump up growth.....           Step therapy changes at Medicare Part B to hit Amgen, Regeneron particularly hard: analysts.....           Pharma watchers on Twitter chat up Johnson & Johnson Xarelto TV ad that seems 'misleading'.....           China targets Cosentyx, Shingrix and Luxturna and 45 other drugs for priority approval.....           Struggling Perrigo OKs plan to hive off prescription business.....           Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi.....           Mylan says plant remediation dictated in part by which generics to drop.....           FDA approves first generic under new pathway designed to fight drug price gouging.....           Can a strategic review solve Mylan's problems? Don't count on it.....           Aralez Pharmaceuticals agrees to sell main operating businesses.....           Izana begins phase II proof-of-concept study of spinal arthritis drug.....           Roche?s Xolair gets FDA breakthrough status for food allergies.....           AHF files review petition with US Supreme Court on Gilead AIDS drug patent case.....           Samsung commits billions of dollars to building its biologics business.....           Far-fetched fictional pharma study anchors new Netflix series ?Maniac?.....           Cimzia maker UCB signs MyHealthTeams to pump up spondyloarthritis social network.....           Samsung commits billions of dollars to building its biologics business.....           Texas spanks AstraZeneca as a repeat offender in settling Seroquel, Crestor whistleblower suits.....           Novo CEO: Expect U.S. diabetes drug prices to continue their downward spiral next year.....           FDA approves Alnylam?s Onpattro to treat polyneuropathy of hATTR amyloidosis.....           Camber Pharmaceuticals voluntarily recalls Valsartan tablets in US.....           Samsung Bioepis to start phase 1 trial of pancreatitis drug SB26.....           Tainted valsartan has been on the market for 4 years, FDA discovers.....           With patisiran launch in its sights, Alnylam plots a major hiring spree.....           Cha-ching: Small biotechs write some of America's biggest paychecks.....           GlaxoSmithKline chief recruits new CFO Iain Mackay to spearhead cost-cutting effort.....           Tainted valsartan has been on the market for 4 years, FDA discovers.....           With patisiran launch in its sights, Alnylam plots a major hiring spree.....           Express Scripts bars 48 drugs for 2019, hitting AbbVie, Gilead, Boehringer and more.....           Look who?s talking: FDA chief Scott Gottlieb churns out statements by the dozen.....           Acorda inks Ampyra generic settlements as it waits for patent appeal news.....           Ironwood dumps AstraZeneca gout drug Zurampic?and lays off 125 in the process.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Latest news

Professional recognition for Pharmaceutical Science Degrees

The Academy of Pharmaceutical Sciences (APS) is delighted to announce that the pharmaceutical science course at the University of Greenwich has become the first APS accredited course having successfully completed the accreditation process set up by the Academy towards the end of 2017.

This is the first time that a pharmaceutical science course has been accredited in the United Kingdom and it is also, we believe, a world first.

Achieving accreditation gives assurance to students and employers that the course meets the high standards required by the Academy and that these standards will be maintained throughout the 5-year period of accreditation.

APS believes that the accreditation process will raise the profile of pharmaceutical sciences in both academia and industry. The discipline is key in the discovery, development and manufacture of new medicines and as such is central to government initiatives to encourage the pharmaceutical industry to maintain and strengthen its strong base here in the UK.

The Academy will continue to work with other stakeholders to build the science base for the ultimate benefit of patients.

APS events overview

The APS has developed an exciting and informative programme for our events in 2018.

Donít forget to make a note of APS@FIP, linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference.

Please take a look at our programme, with event summaries, below:

7 September 2018 - Hilton Hotel, Glasgow
Linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference, which will take place in the city from the 2 - 6 September 2018. The theme of this conference in 2018 is 'The Science of Differentiated Medicines'.
To learn more and to register, click here

"5 Years of progress in Oral Biopharmaceutics - IMI OrBiTo project and global biopharmaceutics research"
17 September 2018 - AstraZeneca, Granta Park, Cambridge
The APS is pleased to announce this exciting 2 day meeting to review the progress and advances made by the collaborative IMI OrBiTo project . The OrBiTo project started in October 2012 and following a twelve-month non-cost extension phase will finish in October 2018.
To learn more and to register, click here

Industrial Insights 2019
Developability for Biologicals
Inhaled Workshop
3D Printing meeting
Basic Biopharmaceutics workshop 

Follow us
Upcoming Events
7 September 2018
"5 Years of progress in Oral Biopharmaceutics - IMI OrBiTo project and global biopharmaceutics research"
17 - 18 September 2018
APS Developability Workshop
17 - 18 April 2019
APS Industrial Insights 2019
25 - 26 April 2019
10th APS International PharmSci conference 2019
11 - 13 September 2019
Job Vacancies
View all Vacancies
Advertise your job vacancies
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351, Fax: 0116 274 7365, Email:

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.

Privacy Policy:
For details on the data we collect and how we store and process your data please refer to our Privacy Policy.